<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001702921</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001936258</issuerCik>
<issuerName>NewAmsterdam Pharma Co N.V.</issuerName>
<secFileNumber>001-41562</secFileNumber>
<issuerAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">GOOIMEER 2-35</street1>
<city xmlns="http://www.sec.gov/edgar/common">NARRDEN</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">P7</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">1411 DC</zipCode>
</issuerAddress>
<issuerContactPhone>31 0 35-206 2971</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>BCIP Life Sciences Associates, LP</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Former Affiliate</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Goldman Sachs &amp; Co. LLC</name>
<address>
<street1 xmlns="http://www.sec.gov/edgar/common">200 West Street</street1>
<city xmlns="http://www.sec.gov/edgar/common">New York</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">NY</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">10282</zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>32571</noOfUnitsSold>
<aggregateMarketValue>1248446</aggregateMarketValue>
<noOfUnitsOutstanding>113390804</noOfUnitsOutstanding>
<approxSaleDate>12/02/2025</approxSaleDate>
<securitiesExchangeName>Nasdaq</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Ordinary Shares</securitiesClassTitle>
<acquiredDate>12/11/2020</acquiredDate>
<natureOfAcquisitionTransaction>Purchase of ordinary shares in the initial public offering of Frazier Lifesciences Acquisition Corporation, which ordinary shares were automatically exchanged on a 1:1 basis for ordinary shares of the Issuer on November 22, 2022.</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Underwriter</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>32571</amountOfSecuritiesAcquired>
<paymentDate>12/11/2020</paymentDate>
<natureOfPayment>Cash</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<noticeSignature>
<noticeDate>12/02/2025</noticeDate>
<signature>/s/ Adam Koppel, as Authorized Signatory of Boylston Coinvestors, LLC</signature>
</noticeSignature>
</formData>
</edgarSubmission>
